MY160732A - A novel conjugate of granulocyte colony-stimulating factor (g-csf) with polyethylene glycol - Google Patents

A novel conjugate of granulocyte colony-stimulating factor (g-csf) with polyethylene glycol

Info

Publication number
MY160732A
MY160732A MYPI2013000217A MYPI2013000217A MY160732A MY 160732 A MY160732 A MY 160732A MY PI2013000217 A MYPI2013000217 A MY PI2013000217A MY PI2013000217 A MYPI2013000217 A MY PI2013000217A MY 160732 A MY160732 A MY 160732A
Authority
MY
Malaysia
Prior art keywords
stimulating factor
granulocyte colony
csf
polyethylene glycol
conjugate
Prior art date
Application number
MYPI2013000217A
Inventor
Tatyana Veniaminovna Chernovskaya
Lev Alexandrovich Denisov
Dmitriy Valentinivich Morozov
Elena Georgievna Rudenko
Elena Leonidovna Morozova
Original Assignee
Closed Joint-Stock Company Biocad (Cjsc Biocad )
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45567857&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY160732(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Closed Joint-Stock Company Biocad (Cjsc Biocad ) filed Critical Closed Joint-Stock Company Biocad (Cjsc Biocad )
Publication of MY160732A publication Critical patent/MY160732A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

THE PRESENT INVENTION RELATES TO PHARMACEUTICALS AND MEDICINE, NAMELY, TO NEW PHYSIOLOGICALLY ACTIVE CONJUGATES OF GRANULOCYTE COLONY-STIMULATING FACTOR (G-CSF) WITH THE GENERAL FORMULA: THE INVENTION IS ALSO RELATED TO MEDICINES CONTAINING THE CLAIMED CONJUGATE OF FORMULA (I), PHARMACEUTICAL COMPOSITIONS, THE USE OF CONJUGATE OF FORMULA (I) FOR DRUGS AND MEDICINES WITH GRANULOCYTE COLONY STIMULATING FACTOR AS AN ACTIVE INGREDIENT, APPROACHES TO PREVENT AND/ OR TREAT NEUTROPENIA, THE CONTAINER THAT COMPRISES PHARMACEUTICAL COMPOSITION.
MYPI2013000217A 2010-08-13 2011-07-19 A novel conjugate of granulocyte colony-stimulating factor (g-csf) with polyethylene glycol MY160732A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2010133875/10A RU2446173C1 (en) 2010-08-13 2010-08-13 New functional, high-purity stable conjugate of granulocyte colony-stimulating factor (g-csf) and polyethylene glycol with prolonged biological action, applicable for medical purposes, and based immunobiological agent

Publications (1)

Publication Number Publication Date
MY160732A true MY160732A (en) 2017-03-15

Family

ID=45567857

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2013000217A MY160732A (en) 2010-08-13 2011-07-19 A novel conjugate of granulocyte colony-stimulating factor (g-csf) with polyethylene glycol

Country Status (17)

Country Link
KR (1) KR101549457B1 (en)
CN (1) CN103140499B (en)
CL (1) CL2013000400A1 (en)
CO (1) CO6670557A2 (en)
CR (1) CR20130020A (en)
CU (1) CU24139B1 (en)
DO (1) DOP2013000003A (en)
EA (1) EA019043B1 (en)
EC (1) ECSP13012399A (en)
MA (1) MA34525B1 (en)
MY (1) MY160732A (en)
NI (1) NI201300007A (en)
PE (1) PE20131085A1 (en)
RS (1) RS20130094A1 (en)
RU (1) RU2446173C1 (en)
SG (1) SG187572A1 (en)
WO (1) WO2012021088A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012110057A1 (en) 2011-02-15 2012-08-23 Chemisches Institut Schaefer Ag Cefuroxime safety kit
US11116738B2 (en) 2012-06-07 2021-09-14 Children's Hospital Los Angeles Methods for treating neutropenia using retinoid agonists
CN103908427B (en) * 2013-01-05 2014-12-17 石药集团百克(山东)生物制药有限公司 Polyethylene glycol modified rhG-CSF injection and preparation method thereof
RU2535002C2 (en) * 2013-04-04 2014-12-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук Method for correction of remote consequences of spermatogenesis caused by cytostatic exposure
US10286039B2 (en) 2014-02-18 2019-05-14 Children's Hospital Los Angeles Compositions and methods for treating neutropenia
PE20220371A1 (en) 2014-07-14 2022-03-16 Gennova Biopharmaceuticals Ltd NOVEL PROCEDURE FOR PURIFICATION OF rHU-GCSF
IL247369B (en) * 2016-08-18 2018-08-30 B G Negev Tech And Applications Ltd Modified m-csf polypeptides and use thereof
KR102020995B1 (en) * 2017-10-30 2019-09-16 한국코러스 주식회사 A method of preparing gcsf and polyol_conjugated conjugates with high yield
KR20220154214A (en) * 2020-03-17 2022-11-21 드럭리큐어 에이피에스 Liquid formulation of GM-CSF for inhalation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE135370T1 (en) * 1988-12-22 1996-03-15 Kirin Amgen Inc CHEMICALLY MODIFIED GRANULOCYTE COLONY EXCITING FACTOR
US5252714A (en) * 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
KR20040083268A (en) * 2003-03-21 2004-10-01 한미약품 주식회사 Human granulocyte-colony stimulating factor conjugate having enhanced stability in blood and process for the preparation thereof
RU2278870C2 (en) * 2004-08-30 2006-06-27 Закрытое Акционерное Общество "Биокад" Method for preparing, isolating, purifying and stabilizing human recombinant granulocytic colony-stimulating factor useful for medicinal using and immunobiological agent based on thereof
WO2007084460A2 (en) * 2006-01-18 2007-07-26 Qps, Llc Pharmaceutical compositions with enhanced stability
JP2009541333A (en) * 2006-06-23 2009-11-26 クインテセンス バイオサイエンシーズ インコーポレーティッド Modified ribonuclease

Also Published As

Publication number Publication date
CN103140499B (en) 2014-12-17
EA201101035A1 (en) 2012-02-28
SG187572A1 (en) 2013-03-28
DOP2013000003A (en) 2013-07-31
NI201300007A (en) 2014-05-26
CR20130020A (en) 2013-02-20
ECSP13012399A (en) 2013-05-31
WO2012021088A1 (en) 2012-02-16
EA019043B1 (en) 2013-12-30
RS20130094A1 (en) 2013-08-30
PE20131085A1 (en) 2013-10-10
CN103140499A (en) 2013-06-05
RU2446173C1 (en) 2012-03-27
KR20130043167A (en) 2013-04-29
CU24139B1 (en) 2015-12-23
KR101549457B1 (en) 2015-09-02
CO6670557A2 (en) 2013-05-15
CU20130012A7 (en) 2013-04-19
MA34525B1 (en) 2013-09-02
CL2013000400A1 (en) 2013-07-26

Similar Documents

Publication Publication Date Title
MY160732A (en) A novel conjugate of granulocyte colony-stimulating factor (g-csf) with polyethylene glycol
NZ605887A (en) Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of neuropathic pain
BR112013003045A2 (en) compound and pharmaceutical composition and uses thereof, sterile container and method for preparing pharmaceutical composition for administration
EA201690102A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING DIMETHYLFUMATE FOR INTRODUCTION TO LOW DAILY DOSE
WO2013101897A3 (en) Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
MX2012007410A (en) Novel antiviral compounds.
MX2011008634A (en) Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy.
MY188598A (en) Dexmedetomidine premix formulation
MY149731A (en) Compounds
NZ595372A (en) Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
MX2011013150A (en) Pharmaceutical composition for use in medical and veterinary ophthalmology.
MX2012008361A (en) Pyrazole compounds as crth2 antagonists.
MX2009013501A (en) Piperidine compounds and uses thereof.
MX2015004362A (en) Ketamine derivatives.
HRP20140591T1 (en) Improved medicinal compositions comprising buprenorphine and nalmefene
MX2014014041A (en) Novel dosage and formulation.
EA201300857A1 (en) PYRAZOLES AS AN ANTAGONISTS CRTH2
EP2682129A3 (en) Compositions Comprising Muscarinic Receptor Antagonist and Glucose Anhydrous
WO2011058245A8 (en) Novel mannopyranoside derivatives with anticancer activity
CY1115600T1 (en) Piperazines as Anthelmintic Agents
BR112012020415A2 (en) pharmaceutical composition for the prevention or treatment of osteoarthritis
MX2015014905A (en) PYRAZINO[1,2-a]INDOLE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS.
PH12015502420A1 (en) PYRAZINO[1,2-a]INDOLE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS
WO2015027669A3 (en) Phenyl-substituted compound, pharmaceutical composition and uses thereof
UA97076C2 (en) Anti-inflammatory ointment based on sulfanilamide